var data={"title":"Ciprofloxacin (ophthalmic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ciprofloxacin (ophthalmic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/231815?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ciprofloxacin-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Ciprofloxacin (ophthalmic): Drug information&quot;</a> and <a href=\"topic.htm?path=ciprofloxacin-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ciprofloxacin (ophthalmic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611239\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ciloxan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611240\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ciloxan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10586564\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Ophthalmic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10586586\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ciprofloxacin-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Ciprofloxacin (ophthalmic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial conjunctivitis; treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ointment: Children &ge;2 years and Adolescents: Apply <sup>1</sup>/<sub>2</sub>&quot; ointment ribbon into the conjunctival sac 3 times daily for 2 days, then twice daily for the next 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: Children &ge;1 year and Adolescents: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) every 2 hours while awake for 2 days, then 1 to 2 drops every 4 hours while awake for the next 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Corneal ulcers; treatment:</b> Solution: Children and Adolescents: Instill 2 drops into the conjunctival sac every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the remainder of the first day; on the second day, 2 drops every hour; on the third day and for the duration of therapy, 2 drops every 4 hours thereafter for a total of 14 days; treatment may continue longer if reepithelialization has not occurred</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial conjunctivitis; treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ointment: Apply <sup>1</sup>/<sub>2</sub>&quot; ointment ribbon into the conjunctival sac 3 times daily for 2 days, then twice daily for the next 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: Instill 1 to 2 drops into the conjunctival sac of the affected eye(s) every 2 hours while awake for 2 days, then 1 to 2 drops every 4 hours while awake for the next 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Corneal ulcers; treatment:</b> Solution: Instill 2 drops into the conjunctival sac every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the remainder of the first day; on the second day, 2 drops every hour; on the third day and for the duration of therapy, 2 drops every 4 hours thereafter. Treatment may continue after day 14 if reepithelialization has not occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611527\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, Ophthalmic, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ciloxan: 0.3% (3.5 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Ophthalmic, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ciloxan: 0.3% (5 mL) [contains benzalkonium chloride, edetate disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.3% (2.5 mL, 5 mL, 10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611242\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10586587\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Ophthalmic: For topical use only. Avoid contacting tip with skin or eye.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ointment: Instill ointment in the lower conjunctival sac.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution: Apply gentle pressure to lacrimal sac during and for 1 to 2 minutes after instillation or instruct patient to gently close eyelid after administration to decrease risk of absorption and systemic effects (Urrti 1993; Zimmerman 1982)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611358\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Protect solution from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10586565\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of bacterial conjunctivitis due to susceptible organisms (Ointment: FDA approved in ages &ge;2 years and adults; Solution: FDA approved in ages &ge;1 year and adults); treatment of corneal ulcers (Solution: FDA approved in ages &ge;1 year and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3198568\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ciprofloxacin may be confused with cephalexin </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ciloxan may be confused with Cytoxan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13854755\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Unpleasant taste (immediately after instillation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Burning sensation of eyes, conjunctival hyperemia, corneal disease, crusting of eyelid, crystalline eye deposits (solution; white crystalline precipitate in superficial portion of corneal defect in those with corneal ulcer; reversible after completion of therapy), eye discomfort, eye pruritus, foreign body sensation of eye</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Blurred vision, corneal infiltrates, corneal staining, dermatitis, epitheliopathy, eye pain, eye irritation, eyelid edema, keratitis, keratoconjunctivitis, lacrimation, nausea, photophobia, vision loss, xerophthalmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611310\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ciprofloxacin, any component of the formulation, or other quinolones</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611311\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Delayed healing: Corneal healing may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Severe hypersensitivity reactions, including anaphylaxis (some fatal), have occurred with quinolone therapy (primarily with systemic use). Prompt discontinuation of drug should occur if skin rash or other symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection. If superinfection is suspected, institute appropriate alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should not be worn during treatment of ophthalmologic infections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ophthalmic use: For ophthalmic use only. Not for subconjunctival  injection or for introduction into the anterior chamber of the eye. To avoid contamination, do not touch tip of container to any surface.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299045\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611335\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15950&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611268\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611269\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. When administered orally or IV, ciprofloxacin crosses the placenta (Giamarellou 1989; Ludlam 1997). The amount of ciprofloxacin available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral or IV doses. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion for 3 to 5 minutes after application to decrease potential exposure to the fetus (Samples 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611376\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611379\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Absorption: Only small amounts are absorbed systemically after ophthalmic instillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9611529\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Ciloxan Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3% (3.5 g): $257.23</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ciloxan Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3% (5 mL): $145.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ciprofloxacin HCl Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3% (2.5 mL): $24.90</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961928\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alcon Cilox (CO, ID);</li>\n      <li>Aprocin (HK);</li>\n      <li>Baquinor (ID);</li>\n      <li>Beuflox (LK);</li>\n      <li>Ceflox (IN);</li>\n      <li>Cetraflux (ES);</li>\n      <li>Cifloptic (PE);</li>\n      <li>Cifran DPS (IN);</li>\n      <li>Cilobact (CO);</li>\n      <li>CiloQuin (AU);</li>\n      <li>Cilox (NO);</li>\n      <li>Ciloxan (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CY, CZ, DE, DK, EE, EG, FR, GB, GR, HR, HU, IE, IL, JO, KW, LB, LK, LT, LU, LV, MT, MY, NL, NZ, PH, PK, PL, PY, QA, SA, SE, SK, TH, TR, TW, UY, VE, VN, ZA, ZW);</li>\n      <li>Cipcin (BD, TW);</li>\n      <li>Ciplox (ET, LK);</li>\n      <li>Ciplus (KR);</li>\n      <li>Cipro (LK);</li>\n      <li>Ciprocin (EG);</li>\n      <li>Ciprodar (HK, JO, SA);</li>\n      <li>Ciprolak (PE);</li>\n      <li>Ciprotal (PH);</li>\n      <li>Ciroxin (TW);</li>\n      <li>Ifloxin (PH);</li>\n      <li>Interflox (ID);</li>\n      <li>Neofloxin (BD);</li>\n      <li>Novaflox (SG);</li>\n      <li>Oftacilox (PT);</li>\n      <li>Optal-Pro (TH);</li>\n      <li>Opticin (AE, JO, KW, QA);</li>\n      <li>Qiu Lu (CN);</li>\n      <li>Quinoryl (PH);</li>\n      <li>Sophixin Ofteno (CR, DO, GT, HN, NI, PA, SV, VE);</li>\n      <li>Vistaflox (PH);</li>\n      <li>Xcipro (MY);</li>\n      <li>Ximex Cyclowam (ID);</li>\n      <li>Zoxan (ET)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ciloxan ointment (ciprofloxacin ophthalmic) [prescribing information]. Forth Worth, TX: Alcon Laboratories, Inc.; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ciprofloxacin Ophthalmic Solution 0.3% as Base [prescribing information]. Buffalo Grove, IL: Pack Pharmaceuticals, LLC.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ciprofloxacin Ophthalmic Solution (ciprofloxacin ophthalmic) [prescribing information]. Lake Forest, IL: Akorn, Inc.; February 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giamarellou H, Kolokythas E, Petrikkos G, et al. &quot;Pharmacokinetics of Three Newer Quinolones in Pregnant and Lactating Women,&quot; Ciprofloxacin: major advances in intravenous and oral quinolone therapy. Proceedings of a symposium. April 28 to 29, 1989, Naples, Florida.<i> Am J Med</i>. 1989; 87(5A):49S-51S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/2589353/pubmed\" target=\"_blank\" id=\"2589353\">2589353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludlam H, Wreghitt TG, Thornton S. Q fever in pregnancy. <i>J Infect</i>. 1997;34(1):75-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/9120330 /pubmed\" target=\"_blank\" id=\"9120330 \">9120330 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. <i>Am J Ophthalmol</i>. 1988;106(5):616-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/2903673 /pubmed\" target=\"_blank\" id=\"2903673 \">2903673 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol.</i> 1993;37(6):435-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/8100087/pubmed\" target=\"_blank\" id=\"8100087\">8100087</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984 102(4):551-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ciprofloxacin-ophthalmic-pediatric-drug-information/abstract-text/6704011/pubmed\" target=\"_blank\" id=\"6704011\">6704011</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15950 Version 125.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F9611239\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9611240\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10586564\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10586586\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9611527\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9611242\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10586587\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9611358\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10586565\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3198568\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13854755\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9611310\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9611311\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299045\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9611335\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F9611268\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9611269\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9611376\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9611379\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F9611529\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961928\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15950|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ciprofloxacin-ophthalmic-drug-information\" class=\"drug drug_general\">Ciprofloxacin (ophthalmic): Drug information</a></li><li><a href=\"topic.htm?path=ciprofloxacin-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">Ciprofloxacin (ophthalmic): Patient drug information \t</a></li></ul></div></div>","javascript":null}